When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne.
The Boston life sciences industry is flourishing, according to Jones Lang Lasalle, a multinational firm that advises life sciences companies on business strategies. Last year the company produced the first comprehensive, global life sciences ‘cluster’ report, with a heavy focus on the US.
It argued that, statistically, Boston and its surrounding area was the highest-ranking US industry hub, taking first place in five of six categories including government funding and venture capital funding. On the face of it, accruing 17 points more than second-placed New York-New Jersey, Boston stands far taller and stronger than any of its rivals.
But looking more closely, how dominant is Boston? For example, the town’s life sciences employment as a percentage of its total employment—16.2 percent—is only marginally higher than second-placed Philadelphia’s, at 14.8 percent. And venture capitalists, who are crucial for investing in the life sciences industry, increasingly flock to the San Francisco Bay Area rather than to Boston.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Boston, pharmaceuticals, cluster, MIT, Harvard
